You are here: Industry Insights > Treatment

News List

STELARA Shows Positive Results In Treatment of Systemic Lupus Erythematosus americanpharmaceuticacreview
November 07, 2017
Based on the results of the Phase 2 study results, Janssen plans to advance STELARA into a Phase 3 SLE development program in 2018.
MSF secures generic hepatitis C treatment at $120 expressbpd
November 06, 2017
According to MSF, dramatic price drop from $147,000 should allow countries to provide treatment for millions of people
Glenmark launches oral drug for psoriasis treatment expressbpd
October 25, 2017
Glenmark Pharmaceuticals has launched Apremilast, the first advanced oral systemic treatment for psoriasis in India.
US FDA approves AbbVie's imbruvica for treatment of adults with cGVHD pharmaceutical-technology
August 07, 2017
The US Food and Drug Administration (FDA) has expanded the approval of imbruvica (ibrutinib) for the treatment of adult patients with chronic graft-versus-host-disease (cGVHD) after the failure of one or more treatments.
1 in 6 US patients are given wrong dose of blood-thinners, study suggests June 07, 2017
New research data from the Mayo Clinic has suggested that as much as one in six patients suffering from atrial fibrillation have been prescribed the wrong dose of blood-thinning medication as a treatment.
Breakthrough treatment for ovarian cancer displays promising results pharmafile
June 06, 2017
A treatment that specifically targets ovarian cancer cells has shown that half of women who took the drug experienced shrinking of their tumours. In the cases where women possessed a particular molecular target, seven out of ten women were found to respon
Roche denies its acne treatment led to suicide of 21 year old pharmafile
May 05, 2017
Last month, Luke Reeves took his own life at the age of just 21. Prior to his death, he had been using Roche’s...
First new promising treatment in a decade for primary liver cancer patients europeanpharmaceuticalreview
May 02, 2017
Results of the SARAH trial demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular carcinoma (HCC).
EU recommendation for Sanofi and Regeneron's arthritis treatment pharmafile
April 25, 2017
Sanofi and Regeneron are celebrating the news that their treatment Kevzara (sarilumab) has received...
New prognostic tool accurately predicts kidney failure risk pharmafile
April 20, 2017
Researchers from the Joslin Diabetes Center (JDC) have developed a prognostic tool which they claim can accurately...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page